T cell immunomodulation-the Holy Grail of therapeutic tolerance

Current Opinion in Pharmacology

Volumn 7, Issue 4, 2007, Pages 418-425

  Isaacs, John D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALEFACEPT; ALEMTUZUMAB; ANTIINFLAMMATORY AGENT; CD28 ANTIGEN; CYCLOOXYGENASE 2 INHIBITOR; EFALIZUMAB; GLUCOCORTICOID; HEAT SHOCK PROTEIN 60; INFLIXIMAB; INSULIN; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; NATALIZUMAB; OKT 3; PEPTIDE DERIVATIVE; PLACEBO; PROTEIN DNAJ; TGN 1412; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DENDRITIC CELL; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG POTENTIATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY ALLOGRAFT REJECTION; LYMPHOCYTE DEPLETION; MONOTHERAPY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SHORT COURSE THERAPY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; ANTIGENS, CD3; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNE TOLERANCE; ORGAN TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY;

EID: 34548135198     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2007.05.001     Document Type: Review

References (48)

1. Cobbold S., Qin S., Leong L., Martin G., and Waldmann H. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev 129 (1992) 165-201
2. Strand V., Kimberly R., and Isaacs J.D. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 6 (2007) 75-92. This recent review provides a good summary of early attempts to use T-cell specific immunomodulatory therapy, particularly for the management of rheumatoid arthritis.
3. Utset T.O., Auger J.A., Peace D., Zivin R.A., Xu D., Jolliffe L., Alegre M.L., Bluestone J.A., and Clark M.R. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 29 (2002) 1907-1913
4. Friend P.J., Hale G., Chatenoud L., Rebello P., Bradley J., Thiru S., Phillips J.M., and Waldmann H. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 68 (1999) 1632-1637
5. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., Gitelman S.E., Harlan D.M., Xu D., Zivin R.A., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346 (2002) 1692-1698
6. 1c and reduced insulin requirements (compared to the placebo group).
7. Keymeulen B., Vandemeulebroucke E., Ziegler A., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352 (2005) 2598-2608. In patients with recent-onset type 1 diabetes, a 6-day course of aglycosyl anti-CD3 mAb therapy sustained beta-cell function and reduced insulin requirements for 18 months. Efficacy was most marked in those with highest residual beta-cell function at the time of treatment, of whom 75% required only minimal daily insulin supplements throughout follow-up.
8. Herold K.C., Burton J.B., Francois F., Poumian-Ruiz E., Glandt M., and Bluestone J.A. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1 (Ala-Ala). J Clin Invest 111 (2003) 409-418
9. Bisikirska B., Colgan J., Luban J., Bluestone J.A., and Herold K.C. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 115 (2005) 2904-2913. Successful treatment of diabetic subjects with Fc-mutated, anti-CD3 mAb was associated with an expansion of CD8+ T-cells in peripheral blood. These cells had regulatory properties and expressed CTLA4 and FoxP3.
10. Kremer J.M., Dougados M., Emery P., Durez P., Sibilia J., Shergy W., Steinfeld S., Tindall E., Becker J.C., Li T., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 2263-2271. This and the following two papers demonstrate the use of costimulation blockade in patients with rheumatoid arthritis. Improvement in symptoms is accompanied by significant quality of life benefit as well as reduced joint damage.
11. •].
12. •].
13. Isaacs J., Greer S., Sharma S., Symmons D., Smith M., Johnston J., Waldmann H., Hale G., and Hazleman B. Morbidity and mortality in rheumatoid arthritis patients with profound and prolonged therapy-induced lymphopenia. Arthritis Rheum 44 (2001) 1998-2008
14. de Kleer I., Vastert B., Klein M., Teklenburg G., Arkesteijn G., Yung G.P., Albani S., Kuis W., Wulffraat N., and Prakken B. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. Blood 107 (2006) 1696-1702. Autologous stem cell transplantation can provide long-term remission of juvenile idiopathic arthritis. This study demonstrates that treatment is associated with: homeostatic expansion of regulatory T-cells; production of naïve regulatory T-cells; and deviation of autoreactive cells from a pro-inflammatory to a regulatory phenotype.
15. Coles A.J., Cox A., Le Page E., Jones J., Trip S.A., Deans J., Seaman S., Miller D.H., Hale G., Waldmann H., et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253 (2006) 98-108. A good review of the use of CAMPATH-1H in multiple sclerosis patients. A single course of treatment is associated with improvement in disability for up to 36 months.
16. Cox A.L., Thompson S.A., Jones J.L., Robertson V.H., Hale G., Waldmann H., Compston D.A., and Coles A.J. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 35 (2005) 3332-3342
17. Calne R.Y. Prope tolerance-the future of organ transplantation from the laboratory to the clinic. Int Immunopharmacol 5 (2005) 163-167. A brief review of transplantation tolerance with an emphasis on 'almost tolerance'-where graft acceptance is maintained by a low, nontoxic dosage of maintenance immunosuppression, which may not be required indefinitely.
18. Larche M., and Wraith D.C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 11 (2005) S69-S76. An excellent review of the state-of-the-art with respect to the use of synthetic peptide vaccines for the treatment of autoimmune and allergic diseases.
19. Kamphuis S., Kuis W., de Jager W., Teklenburg G., Massa M., Gordon G., Boerhof M., Rijkers G.T., Uiterwaal C.S., Otten H.G., et al. Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 366 (2005) 50-56
20. Raz I., Elias D., Avron A., Tamir M., Metzger M., and Cohen I.R. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358 (2001) 1749-1753
21. 1c levels were similar to those in the placebo group.
22. Huurman V.A., Decochez K., Mathieu C., Cohen I.R., and Roep B.O. Therapy with the hsp60 peptide DiaPep277 (trade mark) in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev (2006)
23. Nussbaum G., Zanin-Zhorov A., Quintana F., Lider O., and Cohen I.R. Peptide p277 of HSP60 signals T cells: inhibition of inflammatory chemotaxis. Int Immunol 18 (2006) 1413-1419. This paper suggests that some of the effects of an HSP-derived peptide may reflect signalling through TLR-2 on T-cells. This results in increased adhesion and reduced chemotaxis, potentially reducing the trafficking of T-cells into inflamed tissues.
24. Alexander C., Tarzi M., Larche M., and Kay A.B. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 60 (2005) 1269-1274. Multiple, short, overlapping peptides derived from the major cat allergen, Fel d 1, were administered by intradermal injection to cat-allergic asthmatics. This was a small study (8 patients received peptide mixture and 8 placebo) but active treatment was associated with significant decreases in the late asthmatic reaction to whole cat dander as well as significant improvements in asthma quality of life scores. The next reference suggests that treatment may induce a T-cell population with specific regulatory/suppressor activity.
25. •].
26. Prakken B.J., Samodal R., Le T.D., Giannoni F., Yung G.P., Scavulli J., Amox D., Roord S., de Kleer I., Bonnin D., et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci USA 101 (2004) 4228-4233
27. Beyersdorf N., Gaupp S., Balbach K., Schmidt J., Toyka K.V., Lin C.H., Hanke T., Hunig T., Kerkau T., and Gold R. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 202 (2005) 445-455
28. Hunig T., and Dennehy K. CD28 superagonists: mode of action and therapeutic potential. Immunol Lett 100 (2005) 21-28. A good review of the therapeutic potential of CD28 superagonists.
29. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., and Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 (2006) 1018-1028. The report of the devastating effects of a first-into-man study of a CD28 superagonist. Treatment was associated with a life-threatening cytokine storm in all recipients of active drug. This paper demonstrates the hazards inherent in translating pre-clinical findings of T-cell immunomodulators to the clinic.
30. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., Gran B., Eaton J., Antel J., Frank J.A., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6 (2000) 1167-1175
31. Kappos L., Comi G., Panitch H., Oger J., Antel J., Conlon P., and Steinman L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 6 (2000) 1176-1182
32. Weinblatt M., Combe B., Covucci A., Aranda R., Becker J.C., and Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 54 (2006) 2807-2816. Abatacept in combination with non-biological anti-rheumatic drugs was well tolerated. When abatacept was administered to patients receiving biological (anti-TNFα or anti-IL1β) therapy, however, the rate of serious adverse events increased considerably.
33. Bluestone J.A., and Tang Q. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc Natl Acad Sci USA 101 Suppl. 2 (2004) 14622-14626
34. Horwitz D.A., Zheng S.G., Gray J.D., Wang J.H., Ohtsuka K., and Yamagiwa S. Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin Immunol 16 (2004) 135-143
35. Steiner D., Brunicki N., Blazar B.R., Bachar-Lustig E., and Reisner Y. Tolerance induction by third-party "off-the-shelf" CD4+CD25+ Treg cells. Exp Hematol 34 (2006) 66-71
36. van Duivenvoorde L.M., van Mierlo G.J., Boonman Z.F., and Toes R.E. Dendritic cells: vehicles for tolerance induction and prevention of autoimmune diseases. Immunobiology 211 (2006) 627-632
37. Quinn M., Conaghan P., O'Connor P., Karim Z., Greenstein A., Brown A., Brown C., Fraser A., Jarret S., and Emery P. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomised, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005) 27-35. In established rheumatoid arthritis, anti-TNFα therapy is required indefinitely, to avoid disease flares on treatment withdrawal. In this study, treatment for 12 months in patients with recent-onset rheumatoid arthritis was associated with continued benefit for a further 12 months.
38. Ehrenstein M., Evans J., Singh A., Moore S., Warnes G., Isenberg D., and Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy. J Exp Med 200 (2004) 277-285
39. Nadkarni S., Mauri C., and Ehrenstein M.R. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 204 (2007) 33-39. In a follow-up to Reference [38], the authors suggest that treatment with infliximab results in the development of a novel regulatory T-cell subset. This is CD4+CD25hiFoxP3+, mediates suppression via transforming growth factor (TGF)-β and interleukin 10, and lacks CD62L expression.
40. Bresson D., Togher L., Rodrigo E., Chen Y., Bluestone J.A., Herold K.C., and von Herrath M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 116 (2006) 1371-1381. In a mouse model of diabetes combining anti-CD3 mAb therapy with intra-nasal proinsulin peptide provided more potent benefit than ether treatment alone. Furthermore, therapy was associated with expansion of CD25+Foxp3+ and insulin-specific regulatory T-cells producing IL-10, TGF-β, and IL-4.
41. Kleinschmidt-DeMasters B.K., and Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353 (2005) 369-374
42. MacDonald JK, McDonald JWD. Natalizumab for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD006097. DOI: 10.1002/14651858.CD006097.pub2.
43. Ortonne J.P., Shear N., Shumack S., and Henninger E. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol 5 (2005) 13. This paper and the next paper demonstrate that blocking LFA-1 for 12 weeks with a humanised mAb improves moderate-to-severe psoriasis, including those with refractory disease.
44. •].
45. Takiguchi R., Tofte S., Simpson B., Harper E., Blauvelt A., Hanifin J., and Simpson E. Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 56 (2007) 222-227
46. Mease P.J., Gladman D.D., and Keystone E.C. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 54 (2006) 1638-1645. 12 weeks of treatment with alefacept, which blocks the interaction between CD2 and LFA-3, was associated with benefit in joint symptoms at 24 weeks and in skin score at 14 weeks.
47. Graves J.E., Nunley K., and Heffernan M.P. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol 56 (2007) e55-e79
48. Newberry R.D., Stenson W.F., and Lorenz R.G. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat Med 5 (1999) 900-906